Your browser doesn't support javascript.
loading
Treatment of lymphangiomas by means of sclerotherapy with OK-432 (Picibanil®) is safe and effective - A retrospective case series.
Fasching, G; Dollinger, C; Spendel, S; Tepeneu, N F.
Afiliación
  • Fasching G; Department of Pediatric and Adolescent Surgery, General Hospital Klagenfurt, Austria, Feschnigstraße 11, 9020, Klagenfurt, Austria.
  • Dollinger C; Department of Pediatric and Adolescent Surgery, General Hospital Klagenfurt, Austria, Feschnigstraße 11, 9020, Klagenfurt, Austria.
  • Spendel S; Division of Plastic Aestetic and Reconstructive Surgery, Medical University of Graz, Auenbruggerplatz 2/4, 8036, Graz, Austria.
  • Tepeneu NF; Department of Pediatric and Adolescent Surgery, General Hospital Klagenfurt, Austria, Feschnigstraße 11, 9020, Klagenfurt, Austria.
Ann Med Surg (Lond) ; 81: 104531, 2022 Sep.
Article en En | MEDLINE | ID: mdl-36147081
Introduction: Congenital cystic lymphangiomas (CCL) or lymphatic malformations (LMs) are benign malformations due to a developmental disorder of lymphatic vessels. Besides surgical excision, sclerosant therapy of these lesions by intracavitary injection of OK-432 (Picibanil®), a lyophilized mixture of group A Streptococcus pyogenes, is a common therapeutical option. Methods: In a single center retrospective study we analyzed 37 consecutive patients (30 children, 3 adolescents and 4 adults) who were diagnosed with lymphangioma and subsequently treated with OK-432 (Picibanil®) in a general hospital between October 2000 and November 2021. Results: The median follow-up period was 2.5 months (range 0.7-56.7 months). The lymphangiomas were localized in the head and neck region (n = 25), the thorax/abdomen (n = 6) and extremities (n = 6). The majority of patients had 1 injection with OK-432 (n = 28), five patients had 2 injections, three patients had 3 injections and one patient had more than 3 injections. The most common complications were swelling (89%), fever (81%), redness at the injection site (81%) and pain (73%). The response to therapy was excellent or good in 32 patients (86.4%), 2 patients had a medium response and 3 patients did not show any response. The clinical reaction after the instillation of OK-432 is not predictive for the quality of outcome. Conclusion: The application of Picibanil is safe and without serious side effects. Parents and patients prefer local sclerotherapy versus surgery as it has less complications. We therefore suggest that Picibanil sclerotherapy should be the first-line treatment for macrocystic and mixed type lymphangiomas.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Ann Med Surg (Lond) Año: 2022 Tipo del documento: Article País de afiliación: Austria Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Ann Med Surg (Lond) Año: 2022 Tipo del documento: Article País de afiliación: Austria Pais de publicación: Reino Unido